Global Sustained Release Injectables Industry Growth and Trends Forecast to 2031
Description
Summary
According to APO Research, The global Sustained Release Injectables market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Sustained Release Injectables include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Sustained Release Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sustained Release Injectables.
The Sustained Release Injectables market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Sustained Release Injectables market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Sustained Release Injectables Segment by Company
Sanofi
Novartis
Merck
Luye Pharma Group
Roche
Livzon Pharm
Eli Lilly
AstraZeneca
Xbrane Biopharma
Taiwan Liposome Company (TLC)
Recipharm AB
PhaseBio Pharmaceuticals
Pacira
OctoPlus
Oakwood Laboratories/PharmaSophia
NanOlogy
Janssen
Ipsen
InnoCore Pharmaceuticals
Enzon
Durect
Critical Pharmaceuticals
Camurus
Biomarin
Avadel
Aurobindo
Ascendis Pharma
AntriaBio
Amylin Pharmaceuticals
Alkermes
Sustained Release Injectables Segment by Type
Gels
Microparticles
Implants
Sustained Release Injectables Segment by Application
Oncology
CNS
Acromegaly
Ophthalmology
Diabetes
Reproductive Health
Rheumatology
Leukemia
Others
Sustained Release Injectables Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Sustained Release Injectables companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Sustained Release Injectables market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.
North American market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Asia-Pacific market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
Europe market for Sustained Release Injectables is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.
The major global companies of Sustained Release Injectables include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Sustained Release Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sustained Release Injectables.
The Sustained Release Injectables market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Sustained Release Injectables market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Sustained Release Injectables Segment by Company
Sanofi
Novartis
Merck
Luye Pharma Group
Roche
Livzon Pharm
Eli Lilly
AstraZeneca
Xbrane Biopharma
Taiwan Liposome Company (TLC)
Recipharm AB
PhaseBio Pharmaceuticals
Pacira
OctoPlus
Oakwood Laboratories/PharmaSophia
NanOlogy
Janssen
Ipsen
InnoCore Pharmaceuticals
Enzon
Durect
Critical Pharmaceuticals
Camurus
Biomarin
Avadel
Aurobindo
Ascendis Pharma
AntriaBio
Amylin Pharmaceuticals
Alkermes
Sustained Release Injectables Segment by Type
Gels
Microparticles
Implants
Sustained Release Injectables Segment by Application
Oncology
CNS
Acromegaly
Ophthalmology
Diabetes
Reproductive Health
Rheumatology
Leukemia
Others
Sustained Release Injectables Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Sustained Release Injectables companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
124 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Sustained Release Injectables Market Size Overview by Region 2020 VS 2024 VS 2031
- 1.4 Global Sustained Release Injectables Market Size by Region (2020-2031)
- 1.4.1 Global Sustained Release Injectables Market Size by Region (2020-2025)
- 1.4.2 Global Sustained Release Injectables Market Size by Region (2026-2031)
- 1.5 Key Regions Sustained Release Injectables Market Size (2020-2031)
- 1.5.1 North America Sustained Release Injectables Market Size Growth Rate (2020-2031)
- 1.5.2 Europe Sustained Release Injectables Market Size Growth Rate (2020-2031)
- 1.5.3 Asia-Pacific Sustained Release Injectables Market Size Growth Rate (2020-2031)
- 1.5.4 South America Sustained Release Injectables Market Size Growth Rate (2020-2031)
- 1.5.5 Middle East & Africa Sustained Release Injectables Market Size Growth Rate (2020-2031)
- 2 Sustained Release Injectables Market by Type
- 2.1 Type Introduction
- 2.1.1 Gels
- 2.1.2 Microparticles
- 2.1.3 Implants
- 2.2 Global Sustained Release Injectables Market Size by Type
- 2.2.1 Global Sustained Release Injectables Market Size Overview by Type (2020-2031)
- 2.2.2 Global Sustained Release Injectables Historic Market Size Review by Type (2020-2025)
- 2.2.3 Global Sustained Release Injectables Market Size Forecasted by Type (2026-2031)
- 2.3 Global Sustained Release Injectables Market Size by Regions
- 2.3.1 North America Sustained Release Injectables Market Size Breakdown by Type (2020-2025)
- 2.3.2 Europe Sustained Release Injectables Market Size Breakdown by Type (2020-2025)
- 2.3.3 Asia-Pacific Sustained Release Injectables Market Size Breakdown by Type (2020-2025)
- 2.3.4 South America Sustained Release Injectables Market Size Breakdown by Type (2020-2025)
- 2.3.5 Middle East and Africa Sustained Release Injectables Market Size Breakdown by Type (2020-2025)
- 3 Sustained Release Injectables Market by Application
- 3.1 Type Introduction
- 3.1.1 Oncology
- 3.1.2 CNS
- 3.1.3 Acromegaly
- 3.1.4 Ophthalmology
- 3.1.5 Diabetes
- 3.1.6 Reproductive Health
- 3.1.7 Rheumatology
- 3.1.8 Leukemia
- 3.1.9 Others
- 3.2 Global Sustained Release Injectables Market Size by Application
- 3.2.1 Global Sustained Release Injectables Market Size Overview by Application (2020-2031)
- 3.2.2 Global Sustained Release Injectables Historic Market Size Review by Application (2020-2025)
- 3.2.3 Global Sustained Release Injectables Market Size Forecasted by Application (2026-2031)
- 3.3 Global Sustained Release Injectables Market Size by Regions
- 3.3.1 North America Sustained Release Injectables Market Size Breakdown by Application (2020-2025)
- 3.3.2 Europe Sustained Release Injectables Market Size Breakdown by Application (2020-2025)
- 3.3.3 Asia-Pacific Sustained Release Injectables Market Size Breakdown by Application (2020-2025)
- 3.3.4 South America Sustained Release Injectables Market Size Breakdown by Application (2020-2025)
- 3.3.5 Middle East and Africa Sustained Release Injectables Market Size Breakdown by Application (2020-2025)
- 4 Global Market Dynamics
- 4.1 Sustained Release Injectables Industry Trends
- 4.2 Sustained Release Injectables Industry Drivers
- 4.3 Sustained Release Injectables Industry Opportunities and Challenges
- 4.4 Sustained Release Injectables Industry Restraints
- 5 Competitive Insights by Company
- 5.1 Global Top Players by Sustained Release Injectables Revenue (2020-2025)
- 5.2 Global Sustained Release Injectables Industry Company Ranking, 2023 VS 2024 VS 2025
- 5.3 Global Sustained Release Injectables Key Company Headquarters & Area Served
- 5.4 Global Sustained Release Injectables Company, Product Type & Application
- 5.5 Global Sustained Release Injectables Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Sustained Release Injectables Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Sustained Release Injectables Players Market Share by Revenue in 2024
- 5.6.3 2024 Sustained Release Injectables Tier 1, Tier 2, and Tier 3
- 6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Comapny Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.1.4 Sanofi Sustained Release Injectables Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Novartis
- 6.2.1 Novartis Comapny Information
- 6.2.2 Novartis Business Overview
- 6.2.3 Novartis Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.2.4 Novartis Sustained Release Injectables Product Portfolio
- 6.2.5 Novartis Recent Developments
- 6.3 Merck
- 6.3.1 Merck Comapny Information
- 6.3.2 Merck Business Overview
- 6.3.3 Merck Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.3.4 Merck Sustained Release Injectables Product Portfolio
- 6.3.5 Merck Recent Developments
- 6.4 Luye Pharma Group
- 6.4.1 Luye Pharma Group Comapny Information
- 6.4.2 Luye Pharma Group Business Overview
- 6.4.3 Luye Pharma Group Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.4.4 Luye Pharma Group Sustained Release Injectables Product Portfolio
- 6.4.5 Luye Pharma Group Recent Developments
- 6.5 Roche
- 6.5.1 Roche Comapny Information
- 6.5.2 Roche Business Overview
- 6.5.3 Roche Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.5.4 Roche Sustained Release Injectables Product Portfolio
- 6.5.5 Roche Recent Developments
- 6.6 Livzon Pharm
- 6.6.1 Livzon Pharm Comapny Information
- 6.6.2 Livzon Pharm Business Overview
- 6.6.3 Livzon Pharm Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.6.4 Livzon Pharm Sustained Release Injectables Product Portfolio
- 6.6.5 Livzon Pharm Recent Developments
- 6.7 Eli Lilly
- 6.7.1 Eli Lilly Comapny Information
- 6.7.2 Eli Lilly Business Overview
- 6.7.3 Eli Lilly Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.7.4 Eli Lilly Sustained Release Injectables Product Portfolio
- 6.7.5 Eli Lilly Recent Developments
- 6.8 AstraZeneca
- 6.8.1 AstraZeneca Comapny Information
- 6.8.2 AstraZeneca Business Overview
- 6.8.3 AstraZeneca Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.8.4 AstraZeneca Sustained Release Injectables Product Portfolio
- 6.8.5 AstraZeneca Recent Developments
- 6.9 Xbrane Biopharma
- 6.9.1 Xbrane Biopharma Comapny Information
- 6.9.2 Xbrane Biopharma Business Overview
- 6.9.3 Xbrane Biopharma Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.9.4 Xbrane Biopharma Sustained Release Injectables Product Portfolio
- 6.9.5 Xbrane Biopharma Recent Developments
- 6.10 Taiwan Liposome Company (TLC)
- 6.10.1 Taiwan Liposome Company (TLC) Comapny Information
- 6.10.2 Taiwan Liposome Company (TLC) Business Overview
- 6.10.3 Taiwan Liposome Company (TLC) Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.10.4 Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio
- 6.10.5 Taiwan Liposome Company (TLC) Recent Developments
- 6.11 Recipharm AB
- 6.11.1 Recipharm AB Comapny Information
- 6.11.2 Recipharm AB Business Overview
- 6.11.3 Recipharm AB Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.11.4 Recipharm AB Sustained Release Injectables Product Portfolio
- 6.11.5 Recipharm AB Recent Developments
- 6.12 PhaseBio Pharmaceuticals
- 6.12.1 PhaseBio Pharmaceuticals Comapny Information
- 6.12.2 PhaseBio Pharmaceuticals Business Overview
- 6.12.3 PhaseBio Pharmaceuticals Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.12.4 PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio
- 6.12.5 PhaseBio Pharmaceuticals Recent Developments
- 6.13 Pacira
- 6.13.1 Pacira Comapny Information
- 6.13.2 Pacira Business Overview
- 6.13.3 Pacira Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.13.4 Pacira Sustained Release Injectables Product Portfolio
- 6.13.5 Pacira Recent Developments
- 6.14 OctoPlus
- 6.14.1 OctoPlus Comapny Information
- 6.14.2 OctoPlus Business Overview
- 6.14.3 OctoPlus Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.14.4 OctoPlus Sustained Release Injectables Product Portfolio
- 6.14.5 OctoPlus Recent Developments
- 6.15 Oakwood Laboratories/PharmaSophia
- 6.15.1 Oakwood Laboratories/PharmaSophia Comapny Information
- 6.15.2 Oakwood Laboratories/PharmaSophia Business Overview
- 6.15.3 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.15.4 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio
- 6.15.5 Oakwood Laboratories/PharmaSophia Recent Developments
- 6.16 NanOlogy
- 6.16.1 NanOlogy Comapny Information
- 6.16.2 NanOlogy Business Overview
- 6.16.3 NanOlogy Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.16.4 NanOlogy Sustained Release Injectables Product Portfolio
- 6.16.5 NanOlogy Recent Developments
- 6.17 Janssen
- 6.17.1 Janssen Comapny Information
- 6.17.2 Janssen Business Overview
- 6.17.3 Janssen Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.17.4 Janssen Sustained Release Injectables Product Portfolio
- 6.17.5 Janssen Recent Developments
- 6.18 Ipsen
- 6.18.1 Ipsen Comapny Information
- 6.18.2 Ipsen Business Overview
- 6.18.3 Ipsen Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.18.4 Ipsen Sustained Release Injectables Product Portfolio
- 6.18.5 Ipsen Recent Developments
- 6.19 InnoCore Pharmaceuticals
- 6.19.1 InnoCore Pharmaceuticals Comapny Information
- 6.19.2 InnoCore Pharmaceuticals Business Overview
- 6.19.3 InnoCore Pharmaceuticals Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.19.4 InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio
- 6.19.5 InnoCore Pharmaceuticals Recent Developments
- 6.20 Enzon
- 6.20.1 Enzon Comapny Information
- 6.20.2 Enzon Business Overview
- 6.20.3 Enzon Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.20.4 Enzon Sustained Release Injectables Product Portfolio
- 6.20.5 Enzon Recent Developments
- 6.21 Durect
- 6.21.1 Durect Comapny Information
- 6.21.2 Durect Business Overview
- 6.21.3 Durect Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.21.4 Durect Sustained Release Injectables Product Portfolio
- 6.21.5 Durect Recent Developments
- 6.22 Critical Pharmaceuticals
- 6.22.1 Critical Pharmaceuticals Comapny Information
- 6.22.2 Critical Pharmaceuticals Business Overview
- 6.22.3 Critical Pharmaceuticals Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.22.4 Critical Pharmaceuticals Sustained Release Injectables Product Portfolio
- 6.22.5 Critical Pharmaceuticals Recent Developments
- 6.23 Camurus
- 6.23.1 Camurus Comapny Information
- 6.23.2 Camurus Business Overview
- 6.23.3 Camurus Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.23.4 Camurus Sustained Release Injectables Product Portfolio
- 6.23.5 Camurus Recent Developments
- 6.24 Biomarin
- 6.24.1 Biomarin Comapny Information
- 6.24.2 Biomarin Business Overview
- 6.24.3 Biomarin Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.24.4 Biomarin Sustained Release Injectables Product Portfolio
- 6.24.5 Biomarin Recent Developments
- 6.25 Avadel
- 6.25.1 Avadel Comapny Information
- 6.25.2 Avadel Business Overview
- 6.25.3 Avadel Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.25.4 Avadel Sustained Release Injectables Product Portfolio
- 6.25.5 Avadel Recent Developments
- 6.26 Aurobindo
- 6.26.1 Aurobindo Comapny Information
- 6.26.2 Aurobindo Business Overview
- 6.26.3 Aurobindo Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.26.4 Aurobindo Sustained Release Injectables Product Portfolio
- 6.26.5 Aurobindo Recent Developments
- 6.27 Ascendis Pharma
- 6.27.1 Ascendis Pharma Comapny Information
- 6.27.2 Ascendis Pharma Business Overview
- 6.27.3 Ascendis Pharma Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.27.4 Ascendis Pharma Sustained Release Injectables Product Portfolio
- 6.27.5 Ascendis Pharma Recent Developments
- 6.28 AntriaBio
- 6.28.1 AntriaBio Comapny Information
- 6.28.2 AntriaBio Business Overview
- 6.28.3 AntriaBio Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.28.4 AntriaBio Sustained Release Injectables Product Portfolio
- 6.28.5 AntriaBio Recent Developments
- 6.29 Amylin Pharmaceuticals
- 6.29.1 Amylin Pharmaceuticals Comapny Information
- 6.29.2 Amylin Pharmaceuticals Business Overview
- 6.29.3 Amylin Pharmaceuticals Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.29.4 Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio
- 6.29.5 Amylin Pharmaceuticals Recent Developments
- 6.30 Alkermes
- 6.30.1 Alkermes Comapny Information
- 6.30.2 Alkermes Business Overview
- 6.30.3 Alkermes Sustained Release Injectables Revenue, Global Share and Gross Margin (2020-2025)
- 6.30.4 Alkermes Sustained Release Injectables Product Portfolio
- 6.30.5 Alkermes Recent Developments
- 7 North America
- 7.1 North America Sustained Release Injectables Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 7.2 North America Sustained Release Injectables Market Size by Country (2020-2025)
- 7.3 North America Sustained Release Injectables Market Size Forecast by Country (2026-2031)
- 8 Europe
- 8.1 Europe Sustained Release Injectables Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 8.2 Europe Sustained Release Injectables Market Size by Country (2020-2025)
- 8.3 Europe Sustained Release Injectables Market Size Forecast by Country (2026-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific Sustained Release Injectables Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 9.2 Asia-Pacific Sustained Release Injectables Market Size by Country (2020-2025)
- 9.3 Asia-Pacific Sustained Release Injectables Market Size Forecast by Country (2026-2031)
- 10 South America
- 10.1 South America Sustained Release Injectables Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 10.2 South America Sustained Release Injectables Market Size by Country (2020-2025)
- 10.3 South America Sustained Release Injectables Market Size Forecast by Country (2026-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa Sustained Release Injectables Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
- 11.2 Middle East & Africa Sustained Release Injectables Market Size by Country (2020-2025)
- 11.3 Middle East & Africa Sustained Release Injectables Market Size Forecast by Country (2026-2031)
- 12 Concluding Insights
- 13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


